The partnership integrates Twist’s antibody services directly into the TuneLab ecosystem. By utilizing preferred protocols, researchers can now leverage TuneLab’s artificial intelligence and machine learning models to accelerate the selection of candidate molecules. This workflow allows for a more efficient transition from digital prediction to the generation of essential wet lab data.

Investors have responded favorably to the expansion of Twist’s technical footprint within the drug discovery pipeline. With the stock currently trading at $144.90, the deal underscores the growing demand for automated, AI-driven platforms in modern biopharmaceutical research.